InvestSMART

Cyclopharm Limited (ASX: CYC) - Announcements

Current share price for CYC : $0.505 0.035 (6.48%)+

ASX company news and announcements for Cyclopharm Limited (CYC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cyclopharm Limited (CYC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cyclopharm Limited (CYC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cyclopharm Limited (CYC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$63 Appendix 4G and Corporate Governance Statement 27 Mar 2026 4:56PM $0.750 $0.505 fallen by 32.67%
$63 Annual Report to shareholders 27 Mar 2026 4:53PM $0.750 $0.505 fallen by 32.67%
$63 CYC Secures Multi-Site Agreement with Northwestern Medicine 24 Mar 2026 8:28AM $0.750 $0.505 fallen by 32.67%
$63 CYC Signs Enterprise Agreement with UPHS 23 Mar 2026 9:16AM $0.720 $0.505 fallen by 29.86%
$63 Change of Director's Interest Notice - KB 12 Mar 2026 1:19PM $0.755 $0.505 fallen by 33.11%
$63 Change of Director's Interest Notice - JW 12 Mar 2026 1:19PM $0.755 $0.505 fallen by 33.11%
$63 Change of Director's Interest Notice - DA 12 Mar 2026 1:18PM $0.755 $0.505 fallen by 33.11%
$63 Change of Director's Interest Notice - JM 12 Mar 2026 1:17PM $0.755 $0.505 fallen by 33.11%
$63 Change of Director's Interest Notice - DH 12 Mar 2026 1:15PM $0.755 $0.505 fallen by 33.11%
$63 Application for quotation of securities - CYC 12 Mar 2026 10:10AM $0.770 $0.505 fallen by 34.42%
$63 Date of Annual General Meeting 10 Mar 2026 11:21AM $0.710 $0.505 fallen by 28.87%
$63 Response to ASX Aware Letter 9 Mar 2026 11:52AM $0.700 $0.505 fallen by 27.86%
$63 Results of CYC Share Purchase Plan 9 Mar 2026 11:35AM $0.700 $0.505 fallen by 27.86%
$63 Update - Proposed issue of securities - CYC 25 Feb 2026 5:20PM $0.835 $0.505 fallen by 39.52%
$63 Preliminary Final Report 25 Feb 2026 5:12PM $0.835 $0.505 fallen by 39.52%
$63 Chairman David Heaney to Retire at 2026 AGM 25 Feb 2026 5:06PM $0.835 $0.505 fallen by 39.52%
$63 Technegas US Footprint Expanding Across Four Regions 19 Feb 2026 12:31PM $0.910 $0.505 fallen by 44.51%
$63 Technegas Approved at the US National Institutes of Health 18 Feb 2026 12:32PM $0.780 $0.505 fallen by 35.26%
$63 Becoming a substantial holder 13 Feb 2026 4:28PM $0.830 $0.505 fallen by 39.16%
$63 Share Purchase Plan Offer Booklet 12 Feb 2026 9:10AM $0.930 $0.505 fallen by 45.70%
$63 Cleansing Notice 11 Feb 2026 9:18AM $0.930 $0.505 fallen by 45.70%
$63 Application for quotation of securities - CYC 11 Feb 2026 9:14AM $0.930 $0.505 fallen by 45.70%
$63 Proposed issue of securities - CYC 4 Feb 2026 9:41AM $1.170 $0.505 fallen by 56.84%
$63 Cyclopharm Capital Raising Investor Presentation 4 Feb 2026 9:41AM $1.170 $0.505 fallen by 56.84%
$63 Cyclopharm Successfully Completes A$14 million Placement 4 Feb 2026 9:40AM $1.170 $0.505 fallen by 56.84%

26 - 50 of 612 results

Page 2 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.